S ubstance P, a member of the family of tachykmms,'
1s involved m numerous physlologlcal actlvmes, such as neurotransmlssion-neuromodulatlon,*,3 stlmulatlon of salivary secretIon, smooth muscle contraction,5 and vasodilatlon.6.7
The vasochlatory action of substance P 1s endothelmm dependentg9 and is mediated by the neurokmm NK-1 receptors located on the endothehal cells. Besides its vasodllatory properties, m some vascular beds substance P also exerts a contracting action on the vascular smooth muscle lo-12 These vasoactlve properties of substance P enable this peptide to participate m the regulation of blood flow of various organs 5. 6 The participation of endogenous substance P in hypertension has been evaluated by a few mvestlgators, mainly by measurement of the plasma levels of this peptide,'? 14 whereas the pharmacological effects have been explored by administration of synthetic substance P or related analogues 15.16 Reduced plasma levels of this peptlde have been described m both stroke-prone spontaneously hypertensive rats 13 and m human essential hypertennon, 14 suggestmg that elevated blood pressure m these SubJects could be related, at least m part, to the lack of adequate counterregulatory action exerted by this endogenous vasodllator.
Recently, a potent, specific, nonpeptlde antagonist of the NK-1 receptor, devoid of agomstlc actions was synthesized. the compound CP 96,345.17.'8 This has allowed From the Nephrology Division, Federal Umverslty of Silo Paula, Brazil, and Department of Me&me, Boston (Mass) Umverslty Medical Center
Correspondence to Osvaldo Kohlmann, Jr, Nephrology Dlvislon, Federal Umverslty of Slo Paulo, Rua Botucatu, 740,04023-900, SBo Paulo, SP, Brazil 0 1997 Amerlcan Heart Assoclatlon, Inc more precise and systematic evaluation of the physlologlcal properties of endogenous substance P and its partlclpatlon m hypertension In previous studies from our laboratories, we were able to demonstrate that an acute mfuslon of this compound increases blood pressure of DOCA-salt hypertensive rats m the early stages (6 weeks) of the hypertensive state However, when we Infused the same agent m rats at later phases of DOCA-salt hypertension (12 weeks), no wgmficant increases m blood pressure were observed 1~0 These observations suggest that partlclpatlon of substance P m the pathogenesis of certain types of hypertension may vary m different stages of the disease depending on the mechanisms prevailing at each stage.
The aim of this study was to extend our previous observations to other models of expenmental hypertension with different pathogenetic mechanisms by determining the blood pressure and heart rate effects of an acute admmlstratlon of the compound CP 96,345
Animals

Methods
Male Wlstar, Wlstar-Kyoto (WKY), and spontaneously hypertensive rats (SHR) were used m this study Animal weights varied m accordance to the model of hypertension Ammals were housed m cages contammg five rats each They were maintained m a room with constant temperature, 12-hour hght/dark cycles, and with free access to regular rat chow and tap water unless other- 
Hypertension Models
Five experImenta hypertensive models and their appropriate controls were used m tlus study They were prepared as follows
(1) DOCA-salt hypertension was induced m mne unmephrectormzed Wlstar rats weighing 290 to 320 g by weekly subcutaneous mJections of deoxycorticosterone pivalate 20 mglkg body weight and 1% saline to drink instead of tap water Control shamtreated rats (n=6) were also unmephrectonuzed but were injected weekly with distilled water and drank tap water instead of 1% sahne All were studied at the sixth week of hypertension (2) Subtotal nephrectomy hypertension was induced m SIX Wistar rats weighing 300 to 340 g by ligating the upper and lower pole arteries of the left kidney and excising the right kidney They received 1% saline to dnnk ad hbitum Six unmephrectomtzed sham-operated animals, dnnkmg tap water instead of 1% saline, were used as controls Animals were studied at 6 weeks after the surgical procedures (3) One-kidney-one chp renovascular hypertension (1 K-1 C) Six male Wistar rats weighing 180 to 200 g had a silver chp with a gap Size of 0 20 mm placed around the left renal artery and had the right kidney removed. Umnephrectormzed sham-operated animals (n=5) were prepared as controls Six weeks after clipping the renal artery, they received the NK-1 receptor antagonist (4) Two-hdney-one clip renovascular hypertension (2K-1 C) In SIX male Wistar rats weighing 180 to 220 g, a silver clip with a gap Size of 0 20 mm was placed around the left renal artery The right kidney was left intact Controls for this group were seven sham-operated rats They were studied 8 weeks after mduction of hypertension.
(5) SHR SHR at two different ages were studied, young (6 to 8 weeks of age, weight, 180 to 200 g, n=7) and adult (14 to 16 weeks of age; weight, 270 to 310 g, n=7). Normotensive agematched WKY (n=5) were used as controls Antagonism of the (NK-1) Receptor of Substance P The compound 345 [(25', 3S) 
, a potent and specific nonpeptide antagonist of the NK-1 receptor, 17 18 diluted m distilled water was infused mtravenously at a rate of 30 pg kg-' mu-' (12 pL/rnm) for 60 consecutive minutes This dosage was chosen on the basis of previous experiments from our laboratones 19
In unanesthetlzed, unrestrained animals housed m mdividual cages, mean arterial pressure (MAP) and heart rate (HR) were recorded directly m a polygraph (Gould Inc) before and every 5 minutes dunng the 60-minute period of CP 96,345 intravenous infusion Each recorded value represents the mean of five readings obtained during 1 minute of contmuous BP momtormg For these experiments, animals had indwelling catheters placed m the femoral artery (for MAP measurements) and femoral vem (for drug infusion) under light ether anesthesia on the day before the study The catheters were tunneled subcutaneously and extenorlzed at the nape of the animal As previously published, 19 the vehicle infused alone at this rate had no effect on BP of DOCA-salt hypertensive rats, and that was also confirmed m this study m some animals from DOCAsalt and subtotal nephrectomy groups
Results are presented as mean+SD Two-way ANOVA complemented with Mann-Whitney test with a significance level of Also, BP of both young and adult SHR was not slgmfscantly altered by CP 96,345, nor was that of their normotensive control group of WKY (Fig 4) . No significant changes in HR were observed throughout the admuustration of the NK-1 receptor antagonist in any hypertensive or control group (Table) .
Discussion
Our results confirm previous data from our laboratonesr9 demonstrating that m the early phases of DOCA-salt hypertension, acute mhibition of substance P by a potent and specific nonpeptide antagonist of the NK-1 receptor causes sustained increases in BP. The current studies extend these observattons to another two salt-dependent experimental models of hypertension subtotal nephrectomy and lK-1C renovascular hypertension. However, m the 1 K-IC model, the magnitude of BP elevation and duration of the effect were somewhat less than those observed m subtotally nephrectomized and DOCA-salt rats.
On the other hand, our data also indicate that this endogenous vasodilator is not always involved m the pathogenesis of elevated BP. Indeed, the acute admmistration of CP 96,345 given at the same dosage to two other experimental hypertensive models, the 2K-1C renovascular and the SHR, did not cause a significant change m BP Moreover, m spontaneous hypertension, this NK-1 receptor antagonist had no cardiovascular effects m either the early or late stages of hypertension. These observations are m agreement with previous data from our laboratories demonstrating that this antagonist, when infused at later phases of the DOCA-salt hypertension, does not increase BP,20 suggesting that the partictpation of substance P m the pathogenesis of elevated BP could vary according to the phase of the hypertensive state and/or the experimental model.
The BP effect of the antagonist used in the present study was due to blockade of the NK-1 receptor, since m previous studteslg we demonstrated that the enantiomer of this compound, which has been found to be inactive in vitro, did not affect BP m either DOCA-salt or sham-treated animals. This, of course, does not preclude the possibility of a partial nonspecific effect, eg, one mediated via the action of the compound CP 96,345 on the L-type calcium channels 17.1* Also, as previously shown,'9 the antagonist was infused at a rate that completely abolishes the BP response to exogenous substance P given to normal rats.
Therefore, m some experimental models of hypertension, but not m all, the neurotransmitter substance P,*J which also has endothehum-dependent vasodilatory properties,@ appears to be acting as a counterregulatory mechanism against vasoconstriction in an attempt to minimize the elevation m BP These observations would be in keepmg with previous data from the literature, m which reduced plasma levels of substance P were observed m expertmental' and human essential hypertension, 14 suggesting that the elevated BP levels of these entities could be due, at least m part, to msufficient synthesis or release of this endogenous vasodtlator.
Why substance P may be mvolved m some but not all experimental models of hypertension used m the present study remains obscure The common characterrstrc among the three experrmental models, eg, DOCA-salt, subtotally nephrectomrzed, and lK-1C renovascular, m which the NK-I receptor antagonist was able to Increase BP, IS the salt dependency of the hypertensive state On the other hand, spontaneous hypertension and 2K-IC renovascular hypertension are not salt-dependent models This also could be an explanatron for the prevrous observations of our laboratories m later phases of DOCA-salt hypertension, since at that stage the salt dependency of the hypertensive state IS known to be less important The mechanisms by which the sodium dependency could influence the participation of substance P m hypertensive states, eg, direct effects on synthesis/secretion of this endogenous vasodrlator or mdnectly, via central sympathetic strmulatlon, are not known Our current data do not permit further speculatron along these lines An alternatrve explanation for our results that cannot be ruled out 1s a nonspecific effect of CP 96345 on L-type calcium channels. However, m such case, a BP-lowering effect ought to have occurred m all hypertensive models, because calcmm channel blockers are known to affect all types of hypertension. Further studres are necessary to evaluate these possrbrhties.
HR was unaffected by CP 96,345 m all models studred, even m those m which large and sustained Increases m BP were observed durmg the infusion of this NK-1 receptor antagonist, pointing to a lack of baroreflex response m these ammals The reasons and mechanisms for the apparent impairment of baroreflex response after NK-1 antagonist mfusron are not known, and our data do not allow us to explore them However, since substance P is an important neurotransmttter widely distributed at the central nervous system, including the baroreflex complex,2J and CP 96,345 IS able to antagonize NK-1 receptors m the central nervous system,18 an effect of this compound at that level cannot be excluded as an explanation for the lack of an adequate baroreflex response to the acute elevation m BP On the basrs of our present findings, we propose the hypothesis that in some models of experimental hypertensron, substance P could be playing a role as a counterregulatory mechanism against vasoconstrmtron, m an attempt to attenuate the elevation of BP. This participation appears to be strongly mfhtenced by the sodium dependency of the hypertensive state
